We found FGFR2 amplification in 26 (7.2%) patients, of whom 14 (53.8%) were male and 12 (46.2%) were female; 22 (84.6%) had poorly differentiated GC and 4 (15.4%) were well- to moderately differentiated. This evidence concerns the gene FGFR2 and gastric cancer.